Decoy Therapeutics Inc. — Form 8-K
Filed September 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Decoy Therapeutics induced Armistice Capital Master Fund Ltd. to exercise 1,184,434 Series B Milestone Warrants at reduced price of $3.25/share (down from $5.91), generating $3.85M gross proceeds. In return, Decoy issued 2,368,868 new unregistered warrants to Armistice at $3.25 exercise price, 5-year term, exercisable immediately. Exercise prices of all outstanding Series A and Series C Milestone Warrants also reduced to $3.25. Curvature Securities LLC acted as placement agent.
Why this rating
Significant for micro-cap: $3.85M capital raise is ~200% of $1.9M market cap. Dilution via 2.37M new warrants (200% overhang) is material. Positive near-term: immediate cash, reduced warrant exercise prices. Negative long-term: substantial future dilution risk if exercised.
Price action (we called it positive)
before filing · preread $3.98 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.